Shots:
- The US FDA has approved Imaavy to treat antibody +ve gMG pts (≥12yrs.) under priority review based on the ongoing P-III (Vivacity-MG3) trial assessing Imaavy + SoC vs PBO + SoC in antibody +ve or -ve adults (N=199; 153 were Ab +ve); global regulatory review is ongoing
- Trial showed superior disease control per MG-ADL score & a rapid, sustained reduction in autoantibody levels by up to 75% from the 1st dose over 24wks; responses were sustained till 20mos. of follow-up in the ongoing OLE study
- The P-II/III (Vibrance-MG) pediatric trial met its 1EP, with Imaavy (IV, Q2W) + SoC showing a 69% total serum IgG reduction over 24wks. along with 2EPs of improved MG-ADL & QMG scores
Ref: Johnson & Johnson | Image: Johnson & Johnson
Related News:- Johnson & Johnson’s Tremfya Receives the EC’s Approval for Active Ulcerative Colitis (UC)
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click Here for Full Press Release
